Title: Study of Serial Serum Sodium Values in Decompensated Liver Disease Patients during the Phase of Hepatic Encephalopathy
Authors: Gurusamy Gurunamasivayam, Arunkumar Jayakumar, Santhi Thoppappatty Sengottaiyan, Palani Kannan
DOI: https://dx.doi.org/10.18535/jmscr/v5i12.17
Abstract
Background: Hepatic encephalopathy is a dreaded complication of chronic liver disease patients in the decompensated state, associated with high percentage of mortality. Decompensated liver disease is associated with lower serum sodium values than compensated liver disease, though grading of hepatic encephalopathy scales are available, they are clinical and subjective to variation in the clinicians examination.
Aim: This study was done in order to study the corroboration of serum sodium values with various grades of hepatic Encephalopathy and to see the utility of serial serum sodium values as prognostic indicator in the outcome of patients with decompensated liver disease with hepatic Encephalopathy.
Materials and Methods: Study design planned is a Descriptive, case control study. Cases were obtained from the intensive care unit of Govt. Kilpauk Medical college. Controls were enrolled from the outpatient department. The patients with h/o chronic liver disease presenting in decompensated state in Hepatic encephalopathy as per West Haven criteria will be included in the study Patients who are in Hepatic encephalopathy Stage 2-4 are taken. The patients who are in hepatic encephalopathy will be studied from the time of admission for duration of 2 weeks to assess whether they are improving or not. Serial monitoring of the blood parameters will be done tabulated and compared to assess the variation of serum sodium levels during the period of two weeks. At the end of two weeks the mean serum sodium values between those in Hepatic encephalopathy (Grade 2-4) and those in the controls with no or early Hepatic Encephalopathy will be compared.
Results: It is evident that there is an improvement in the mean Serum sodium values from Day 1 to Day 14 in the cases. There is also a shift in the clustering of cases with hepatic encephalopathy from higher grades (4-3) to lower grades (2 – 1) during the course of the study. When the cases and controls were compared there is a significant difference in the fluctuations of the serum sodium levels from day 1 to day 14 in the cases when compared to the control. In both the above statistical tools the probability value 0.05 is considered as significant level.
Conclusion: If not an absolute indicator and also with the lack of high end investigations serum sodium values may serve to be an easily accessible tool to assess the initial condition of patients with hepatic encephalopathy. In resource deficient settings and in physician assessment with conflicting status of the patient, serum sodium may help assess the response to treatment.
Keywords: Hepatic Encephalopathy, Decompensated Liver Disease, West Haven Criteria, Hyponatremia
References
- Weissenborn K, Heidenreich S, Gieweke-meyer K, Rückert N, Hecker H. Memory function in early hepatic encephalopathy. J Hepatol 2003; 39:320–325.
- Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encep-halopathy. Hepatology 2007; 45:549–559.
- Dhiman R, Saraswat VA, Sharma BK, et al. Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for study of the liver. J GastroenterolHepatol 2010; 25:1029–1041.
- Bahceci F, Yildirim B, Karincaoglu M, Dogan I, Sipahi B. Memory impairment in patients with cirrhosis. J Natl Med Assoc 2005; 97:213–216.
- Meyer T, Eshelman A, Abouljoud M. Neuropsychological changes in a large sample of liver transplant candidates. Transplant Proc 2006; 38:3559–3660.
- Binesh N, Huda A, Thomas MA, et al. Hepatic encephalopathy: a neurochemical, neuroanatomical, and neuropsychological study [published online ahead of print February 15, 2006]. J ApplClin Med Phys 2006; 7:86– 96. doi:10.1120/jacmp.v7i1.2151
- Mattarozzi K, Stracciari A, Vignatelli L, D’Alessandro R, Morelli MC, Guarino M. Minimal hepatic encephalopathy: longitu-dinal effects of liver transplantation. Arch Neurol 2004; 61:242–247.
- Kügler CF, Petter J, Taghavy A, et al. Dynamics of cognitive brain dysfunction in patients with cirrhotic liver disease: an event-related P300 potential perspective. Electroencephalogr Clin Neurophysiol 1994; 91:33–41.
- Bajaj JS, Thacker LR, Heuman DM, et al. The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy [published online ahead of print May 23, 2013]. Hepatology 2013; 58:1122–1132. doi:10.1002/hep.26309
- Stroop JR. Studies of interference in serial verbal reactions. J ExpPsychol 1935; 18:643–662.
- Blei AT, Córdoba J; Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalop-athy. Am J Gastroenterol 2001; 96:1968–1976.
- Mas A, Rodés J, Sunyer L, et al; Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.J Hepatol 2003; 38:51–58.
- Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encepha-lopathy.N Engl J Med 2010; 362:1071–1081.
- Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy [published online ahead of print July 23, 2013]. Am J Gastroenterol 2013; 108:1458–1463. doi:10.1038/ajg.2013.219
- Chetri K, Choudhuri G. Role of trace elements in hepatic encephalopathy: zinc and manganese. Indian J Gastroenterol 2003; 22(suppl 2):S28–S30.